DexCom, Inc. (DXCM) is well-poised for growth in the coming quarters, backed by its strong product portfolio. A better-than-expected third-quarter 2024 performance and a series of favorable coverage decisions are expected to contribute further. However, risks related to stiff competition persist.This Zacks Rank #3 (Hold) company’s shares have lost 36.5% year to date against the industry’s 6.7% growth. The S&P 500 Index has soared 28.6% in the same time frame.DXCM, a renowned medical device company and provi ...